Annual EBITDA
-$109.04 M
-$57.12 M-110.03%
31 December 2023
Summary:
Poseida Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$109.04 million, with the most recent change of -$57.12 million (-110.03%) on 31 December 2023. During the last 3 years, it has risen by +$14.64 million (+11.84%). PSTX annual EBITDA is now -475.25% below its all-time high of -$18.95 million, reached on 31 December 2017.PSTX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
$23.89 M
+$51.66 M+186.06%
30 September 2024
Summary:
Poseida Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently $23.89 million, with the most recent change of +$51.66 million (+186.06%) on 30 September 2024. Over the past year, it has increased by +$51.88 million (+185.36%). PSTX quarterly EBITDA is now -67.62% below its all-time high of $73.79 million, reached on 30 September 2022.PSTX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$46.16 M
+$51.88 M+52.92%
30 September 2024
Summary:
Poseida Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$46.16 million, with the most recent change of +$51.88 million (+52.92%) on 30 September 2024. Over the past year, it has increased by +$70.93 million (+60.58%). PSTX TTM EBITDA is now -274.12% below its all-time high of -$12.34 million, reached on 31 March 2019.PSTX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PSTX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -110.0% | +185.4% | +60.6% |
| 3 y3 years | +11.8% | +159.1% | +70.2% |
| 5 y5 years | -158.9% | +221.4% | +22.4% |
PSTX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -110.0% | +11.8% | -67.6% | +142.8% | -201.5% | +70.2% |
| 5 y | 5 years | -158.9% | +11.8% | -67.6% | +142.8% | -201.5% | +70.2% |
| alltime | all time | -475.3% | +11.8% | -67.6% | +142.8% | -274.1% | +70.2% |
Poseida Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $23.89 M(-186.1%) | -$46.16 M(-52.9%) |
| June 2024 | - | -$27.76 M(+34.5%) | -$98.04 M(+4.1%) |
| Mar 2024 | - | -$20.64 M(-4.6%) | -$94.18 M(-13.6%) |
| Dec 2023 | -$109.04 M(+110.0%) | -$21.65 M(-22.7%) | -$109.04 M(-6.9%) |
| Sept 2023 | - | -$27.99 M(+17.1%) | -$117.09 M(+664.8%) |
| June 2023 | - | -$23.90 M(-32.7%) | -$15.31 M(-51.6%) |
| Mar 2023 | - | -$35.49 M(+19.5%) | -$31.64 M(-39.1%) |
| Dec 2022 | -$51.92 M(-55.7%) | -$29.70 M(-140.2%) | -$51.92 M(+177.2%) |
| Sept 2022 | - | $73.79 M(-283.4%) | -$18.73 M(-85.9%) |
| June 2022 | - | -$40.23 M(-27.9%) | -$132.93 M(-2.6%) |
| Mar 2022 | - | -$55.77 M(-1697.2%) | -$136.43 M(+16.5%) |
| Dec 2021 | -$117.06 M | $3.49 M(-108.6%) | -$117.06 M(-24.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | -$40.42 M(-7.6%) | -$154.81 M(+5.1%) |
| June 2021 | - | -$43.73 M(+20.1%) | -$147.27 M(+11.0%) |
| Mar 2021 | - | -$36.40 M(+6.3%) | -$132.63 M(+7.2%) |
| Dec 2020 | -$123.68 M(+51.2%) | -$34.26 M(+4.2%) | -$123.68 M(+10.7%) |
| Sept 2020 | - | -$32.88 M(+13.0%) | -$111.73 M(+13.4%) |
| June 2020 | - | -$29.09 M(+6.0%) | -$98.53 M(+1.7%) |
| Mar 2020 | - | -$27.45 M(+23.1%) | -$96.90 M(+18.5%) |
| Dec 2019 | -$81.78 M(+94.2%) | -$22.31 M(+13.4%) | -$81.78 M(+37.5%) |
| Sept 2019 | - | -$19.67 M(-28.4%) | -$59.48 M(+49.4%) |
| June 2019 | - | -$27.46 M(+122.6%) | -$39.80 M(+222.6%) |
| Mar 2019 | - | -$12.34 M | -$12.34 M |
| Dec 2018 | -$42.12 M(+122.2%) | - | - |
| Dec 2017 | -$18.95 M | - | - |
FAQ
- What is Poseida Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Poseida Therapeutics?
- What is Poseida Therapeutics annual EBITDA year-on-year change?
- What is Poseida Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Poseida Therapeutics?
- What is Poseida Therapeutics quarterly EBITDA year-on-year change?
- What is Poseida Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Poseida Therapeutics?
- What is Poseida Therapeutics TTM EBITDA year-on-year change?
What is Poseida Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of PSTX is -$109.04 M
What is the all time high annual EBITDA for Poseida Therapeutics?
Poseida Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$18.95 M
What is Poseida Therapeutics annual EBITDA year-on-year change?
Over the past year, PSTX annual earnings before interest, taxes, depreciation & amortization has changed by -$57.12 M (-110.03%)
What is Poseida Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of PSTX is $23.89 M
What is the all time high quarterly EBITDA for Poseida Therapeutics?
Poseida Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $73.79 M
What is Poseida Therapeutics quarterly EBITDA year-on-year change?
Over the past year, PSTX quarterly earnings before interest, taxes, depreciation & amortization has changed by +$51.88 M (+185.36%)
What is Poseida Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of PSTX is -$46.16 M
What is the all time high TTM EBITDA for Poseida Therapeutics?
Poseida Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$12.34 M
What is Poseida Therapeutics TTM EBITDA year-on-year change?
Over the past year, PSTX TTM earnings before interest, taxes, depreciation & amortization has changed by +$70.93 M (+60.58%)